Lepu Biopharma Co., Ltd. (HKG:2157)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
5.32
-0.08 (-1.48%)
Apr 29, 2026, 4:08 PM HKT
25.47%
Market Cap 9.60B
Revenue (ttm) 1.04B
Net Income (ttm) 290.85M
Shares Out 1.80B
EPS (ttm) 0.17
PE Ratio 32.10
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,955,000
Average Volume 16,208,154
Open 5.40
Previous Close 5.40
Day's Range 5.28 - 5.47
52-Week Range 3.90 - 10.50
Beta -0.40
RSI 43.25
Earnings Date Mar 25, 2026

About Lepu Biopharma

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of first-in class and best-in-class drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 546
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2157
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.